Related coverage linked through entity extraction aliases.
Jun 19, 2026
Retrospective study analyzed longitudinal data from six immunotherapy-naive MuSK-MG patients over 2013-2024, finding significant positive correlation between MuSK antibody levels and disease severity as measured by MG-ADL scores. The correlation was specific to MuSK antibodies, with total IgG showing no independent relationship.
May 10, 2026
The FDA expanded efgartigimod approval to all adult generalized myasthenia gravis serotypes. Phase 3 ADAPT SERON met its primary endpoint and showed no new safety signals.
May 07, 2026
argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
Dec 11, 2025
Amgen received FDA and European Commission approval for Uplizna to treat generalized myasthenia gravis in adults who are anti-AChR or anti-MuSK antibody positive, offering twice-yearly maintenance dosing after initial loading doses.
